IDEXX Laboratories, Inc. $IDXX Stake Lowered by Montrusco Bolton Investments Inc.

Montrusco Bolton Investments Inc. cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.9% during the third quarter, HoldingsChannel reports. The fund owned 317,110 shares of the company’s stock after selling 55,678 shares during the quarter. IDEXX Laboratories comprises approximately 2.7% of Montrusco Bolton Investments Inc.’s holdings, making the stock its 13th biggest position. Montrusco Bolton Investments Inc.’s holdings in IDEXX Laboratories were worth $165,592,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IDXX. J. Stern & Co. LLP boosted its position in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after buying an additional 23,582 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX traded down $3.63 on Tuesday, hitting $520.31. The company had a trading volume of 445,411 shares, compared to its average volume of 568,993. The stock has a market cap of $40.99 billion, a price-to-earnings ratio of 36.59, a price-to-earnings-growth ratio of 2.77 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The company’s fifty day moving average price is $536.72 and its 200 day moving average price is $552.17. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter last year, the company posted $3.50 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IDXX shares. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Barclays reduced their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Finally, KeyCorp initiated coverage on shares of IDEXX Laboratories in a research note on Monday. They set a “sector weight” rating on the stock. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.